anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To obtain an aging inhibitor excellent in the inhibiting effect on the reduction of function of normal cells accompanying with the aging, and to obtain an oxidative stress inhibitor excellent in the inhibiting effect on the reduction of function of normal cells caused by the oxidative stress.  <P>SOLUTION: The aging inhibitor contains Kangen granules as an active ingredient, and has activities for inhibiting the reduction of function of the normal cells caused by the aging. The oxidative stress inhibitor has activities for inhibiting the reduction of function of the normal cells caused by the oxidative stress. As the activities for inhibiting the reduction of function of the normal cells, an activity for inhibiting the offset of cell cycle, an activity for inhibiting the shortening of segmentation life of the normal cells or an activity for inhibiting the reduction of the survival rate of the normal cells are cited. The Kangen granules are prepared by blending each of the constituting crude drugs consisting of Salvia mitiorrhiza of Labiatae, Cyperus rotundus of Cyperaceae, Aucklandia lappa of Compositae, Carthamus tinctorius of Compositae, Paeonia lactiflora of Paeoniaceae and Cnidium officinalis of Umbelliferae in a prescribed ratio (e.g. 4:1:1:2:2:2, respectively in weight ratio).  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Cisplatin (CDDP) as one of the most common first-line chemotherapy drugs plays a vital role in the treatment of a wide range of malignant tumors. Nevertheless, CDDP resistance is observed as a therapeutic challenge in a large number of cancer patients. Considering the CDDP side effects in normal tissues, predicting the CDDP response of cancer patients can significantly help to choose the appropriate therapeutic strategy. In this regard, investigating the molecular mechanisms involved in CDDP resistance can lead to the introduction of prognostic markers in cancer patients. Matrix metalloproteinases (MMPs) have critical roles in tissue remodeling and cell migration through extracellular matrix degradation. Therefore, defects in MMPs functions can be associated with tumor metastasis and chemo resistance. In the present review, we discussed the role of MMPs in CDDP response and tumor cell invasion. PubMed, Scopus, Google Scholar, and Web of Science were searched using "MMP", "cisplatin", and "cancer" keywords for data retrieval that was limited to Apr 20, 2024. It has been reported that MMPs can increase CDDP resistance in tumor cells as the effectors of PI3K/AKT, MAPK, and NF-κB signaling pathways or independently through the regulation of structural proteins, autophagy, and epithelial-to-mesenchymal transition (EMT) process. This review has an effective role in introducing MMPs as the prognostic markers and therapeutic targets in CDDP-resistant cancer patients.
Topotecan hydrochloride (0.8 mg/m²/day) by mouth for 21 days. Bone marrow will be obtained on approximately Day 28 of Course 1 and 2 and in any course where the CBC suggests that a relapse has occurred. One additional course may be given if the blood is cleared of blasts and the bone marrow is M1, M2 or M3. The patient is off protocol therapy if blasts are still present in the blood and the marrow is M3. Subsequent courses of topotecan may be given only if the bone marrow after Course 2 is M1 or M2. If the bone marrow is M2 on Day 28 of any course, another bone marrow aspirate will be done at the end of the next course. If the patient is in CR, a bone marrow aspirate will be required only every other course unless the peripheral blood suggests that a relapse has occurred. Each subsequent course should begin within six weeks of the start of the previous course.
Desmopressin acetate dosage must be determined for each individual patient and adjusted according to the diurnal pattern of response. Response should be estimated by two parameters: adequate duration of sleep and adequate, not excessive, water turnover. Patients with nasal congestion and blockage have often responded well to intranasal desmopressin acetate. The usual dosage range in adults is 0.1 to 0.4 mL daily, either as a single dose or divided into two or three doses. Most adults require 0.2 mL daily in two divided doses. The morning and evening doses should be separately adjusted for an adequate diurnal rhythm of water turnover. For children aged 3 months to 12 years, the usual dosage range is 0.05 to 0.3 mL daily, either as a single dose or divided into two doses. About 1/4 to 1/3 of patients can be controlled by a single daily dose of desmopressin acetate administered intranasally. Fluid restriction should be observed. (See WARNINGS:, PRECAUTIONS:, Pediatric Use: and Geriatric Use:.)

The nasal spray pump can only deliver doses of 0.1 mL (10 μg) or multiples of 0.1 mL. If doses other than these are required, the rhinal tube delivery system may be used. The spray pump must be primed prior to the first use. To prime pump, press down five (5) times. The bottle will now deliver 10 μg of drug per spray. Discard desmopressin acetate nasal solution after 50 sprays since the amount delivered thereafter per spray may be substantially less than 10 μg of drug.

Geriatric Use: This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. (See CLINICAL PHARMACOLOGY:, Human Pharmacokinetics, CONTRAINDICATION:, and PRECAUTIONS:, Geriatric Use:.)
Polyploidy is thought to enable species diversification and adaptation to extreme environments. Resolving the ecological differences between a taxon's ploidy levels would therefore provide important insights into local adaptation and speciation. The genus Betula includes many polyploids, but estimates of their phylogenetic relationships and evolutionary history are uncertain because of cryptic lineages and species. As one of the southern boundary populations of Betula ermanii in Japan has been shown to have distinctive genetic characteristics and traits, the differences in ploidy levels between three southern boundary and various other Japanese B. ermanii populations were investigated using flow cytometry. Leaf and seed morphologies were also compared. Apart from individuals in southern boundary populations, all those sampled were tetraploid. Individuals from the southern boundary populations were mostly diploid, apart from a few from lower altitude Shikoku populations, which were tetraploid. Leaf and seed morphologies differed between tetraploids and diploids. Diploid individuals were characterized by leaves with a heart-shaped base and many leaf teeth, and seeds with relatively longer wings. The diploid populations could be considered a cryptic relict lineage of B. ermanii, and there is a possibility that this lineage is a diploid ancestor of B. ermanii and a relict population of the Sohayaki element. Further investigation of the Japanese Betula phylogenetic relationships would enable an informed discussion of taxonomic revisions.
OBJECTIVE: To retrospectively explore the clinical significance of radiotherapy to the distant metastatic lymph nodes (cervical/ clavicular/ mediastinal et al.) in metastatic cervical cancer. Hereinto, these cervicothoracic lymph nodes were metastasized from IB1-IVA (initial stage at first treatment), and IVB initially had metastatic disease in these areas at diagnosis.
METHODS: Metastatic cervical cancer only with the distant cervicothoracic metastatic lymph nodes (cervical/ clavicular/ mediastinal et al.), without distant parenchymal organs metastasis such as lung, liver, bone, and peritoneum, were enrolled in the analysis. These patients were classified into IB1-IVA and IVB based on their initial stage of first treatment. All patients received IMRT for the distant metastatic lymph nodes. The progression-free survival (PFS) and overall survival (OS) were analyzed using the Kaplan-Meier method.
RESULTS: Overall, the median PFS was 9 months, and the median OS was 27 months. The subgroup analysis showed that for IB1-IVA, the median PFS was 11 months, and the median OS was 30.5 months. For IVB, the median PFS was 8 months, and the median OS was 16 months.
CONCLUSION: Radiotherapy is beneficial to the distant metastatic lymph nodes (cervical/ clavicular/ mediastinal et al.), and could effectively bring the longer PFS and OS for metastatic cervical cancer.
INTRODUCTION: Postpartum hemorrhage (PPH) remains a major cause of preventable maternal morbidity in the United States. Postpartum hemorrhage simulations were developed to improve provider recognition and treatment; however, there exist few studies that investigate their effects on individual outcomes. Our objective is to estimate the effect of a simulation-based educational intervention on PPH-related maternal morbidity outcomes.
METHODS: We conducted a retrospective cohort analysis of hemorrhage outcomes at a single institution between March 2012 and January 2016 during the implementation of a high-fidelity PPH simulation. Women with PPH defined as an estimated blood loss greater than 500 mL for vaginal delivery and 1000 mL for cesarean delivery were included. The primary outcome was a composite of hemorrhage-related maternal morbidity (maternal death, hysterectomy, intensive care unit admission, blood transfusion, or unanticipated procedures to treat postpartum bleeding). Multivariable logistic regression adjusted for confounding variables between presimulation and postsimulation outcomes.
RESULTS: During the study period, 19,927 deliveries occurred with 4.5% of patients (888) experiencing hemorrhage. Women in the presimulation (n = 278) versus postsimulation groups (n = 610) had similar demographics. Although the PPH rate increased after simulation [2.8% pre vs. 6.1% post, odds ratio (OR), 2.25; 95% confidence interval (CI), 1.95-2.60], composite hemorrhage-related morbidity was lower after simulation training (44% pre vs. 35% post; OR, 0.70; 95% CI, 0.52-0.93). This reduction persisted after adjusting for confounding variables of mode of delivery and time from delivery to first uterotonic use (adjusted OR, 0.66; 95%, CI 0.49-0.89).
CONCLUSIONS: Despite an increased PPH rate, simulation education was associated with a reduction in a hemorrhage-related maternal composite morbidity.
BACKGROUND: Effective treatments for patients with primary biliary cholangitis are limited. Seladelpar, a peroxisome proliferator-activated receptor delta agonist, has potential benefits.
METHODS: In this phase 3, 12-month, double-blind, placebo-controlled trial, we randomly assigned (in a 2:1 ratio) patients who had had an inadequate response to or who had a history of unacceptable side effects with ursodeoxycholic acid to receive oral seladelpar at a dose of 10 mg daily or placebo. The primary end point was a biochemical response, which was defined as an alkaline phosphatase level less than 1.67 times the upper limit of the normal range, with a decrease of 15% or more from baseline, and a normal total bilirubin level at month 12. Key secondary end points were normalization of the alkaline phosphatase level at month 12 and a change in the score on the pruritus numerical rating scale (range, 0 [no itch] to 10 [worst itch imaginable]) from baseline to month 6 among patients with a baseline score of at least 4 (indicating moderate-to-severe pruritus).
RESULTS: Of the 193 patients who underwent randomization and treatment, 93.8% received ursodeoxycholic acid as standard-of-care background therapy. A greater percentage of the patients in the seladelpar group than in the placebo group had a biochemical response (61.7% vs. 20.0%; difference, 41.7 percentage points; 95% confidence interval [CI], 27.7 to 53.4, P<0.001). Normalization of the alkaline phosphatase level also occurred in a greater percentage of patients who received seladelpar than of those who received placebo (25.0% vs. 0%; difference, 25.0 percentage points; 95% CI, 18.3 to 33.2, P<0.001). Seladelpar resulted in a greater reduction in the score on the pruritus numerical rating scale than placebo (least-squares mean change from baseline, -3.2 vs. -1.7; least-squares mean difference, -1.5; 95% CI, -2.5 to -0.5, P = 0.005). Adverse events were reported in 86.7% of the patients in the seladelpar group and in 84.6% in the placebo group, and serious adverse events in 7.0% and 6.2%, respectively.
CONCLUSIONS: In this trial involving patients with primary biliary cholangitis, the percentage of patients who had a biochemical response and alkaline phosphatase normalization was significantly greater with seladelpar than with placebo. Seladelpar also significantly reduced pruritus among patients who had moderate-to-severe pruritus at baseline. The incidence and severity of adverse events were similar in the two groups. (Funded by CymaBay Therapeutics; RESPONSE ClinicalTrials.gov number, NCT04620733; EudraCT number, 2020-004348-27.).
The present invention relates to sweat sensing and the control of sweat sensors for analyzing sweat uptaken by the sweat sensor (600) from a user's skin. The sweat sensor comprises a data receiving unit (602) configured for receiving a user's medical data affecting sweat characteristics. A measurement unit (603) comprises various sensors configured for carrying out based on the sweat uptaken by the sweat sensor, a sweat rate (proxy) measurement. A controller (604) selects one or more of the sensors based on the user's medical data. The present invention uses the insight that the sweat sensor should select the type of sensor depending on the health status of the user. The data receiving unit (602) may be a user interface, a communication interface condition to a database, or a device for measuring the health status of the user directly within the sensor. Measuring the health status can be done, for example, by an SpO 2  sensor, a transcutaneous CO 2  sensor, or an analyte concentration sensor sensing the concentration of the analyte in the uptaken sweat. Since the sweat rate (proxy) sensor is adapted to the medical status of the user, the sweat analysis is more accurate and provides analysis results which are clinically more reliable.
Standard of care for the follow-up, no use of a mobile application or digital therapeutics for the first 12 weeks. After 12 weeks, option is given to the patient to use the mobile app and digital therapeutics are activated for another period of 12 weeks.
Relapsed pediatric B-cell acute lymphoblastic leukemia (B-ALL) remains one of the leading causes of cancer mortality in children. We performed Hi-C, ATAC-seq, and RNA-seq on 12 matched diagnosis/relapse pediatric leukemia specimens to uncover dynamic structural variants (SVs) and 3D chromatin rewiring that may contribute to relapse. While translocations are assumed to occur early in leukemogenesis and be maintained throughout progression, we discovered novel, dynamic translocations and confirmed several fusion transcripts, suggesting functional and therapeutic relevance. Genome-wide chromatin remodeling was observed at all organizational levels: A/B compartments, TAD interactivity, and chromatin loops, including some loci shared by 25% of patients. Shared changes were found to drive the expression of genes/pathways previously implicated in resistance as well as novel therapeutic candidates, two of which (ATXN1 and MN1) we functionally validated. Overall, these results demonstrate chromatin reorganization under the selective pressure of therapy and offer the potential for discovery of novel therapeutic interventions.
NEW MATERIAL:Di- or tri-methoxybenzylpiperazinoalkanol of formula I (R is H or OCH3; n is 2-5) containing ether bond, and its pharmacologically acceptable acid salt. EXAMPLE:N-2-(2-hydroxyethoxy)ethyl-N'-2,3,4-trimethoxybenzylpiperazine hydrochloride salt. USE:Coronary circulation improver. It has pharmacological activity to coronary circulation system such as the suppression of the hypersthenia of cardiac motion, suppression of the constriction of coronary vessel, etc., and is safe as a remedy and preventive for isthemic cardiopathy. It can be administered continuously for the remedy and prevention of the fit of stenocardia. It is extremely safe in an aqueous solution, and the injection of the present compound can be prepared and stored extremely safely. PREPARATION:The compound of formula I can be prepared e.g. by reacting the benzyl halide derivative of formula II (X is halogen) with the piperazine derivative of formula III in the presence of a base at the refluxing temperature of the reaction solvent for several hours.
Subjects in the Group were followed solely during the period of the Fourth-Dose Phase of the study (Study 102015), from Month 10-13 to Month 11-14. Subjects in this Group had been primed with ActHIB™ during Primary Phase of the study (study 101858) and received at Month 10-13 a fourth dose of ActHIB™ and a concomitant fourth dose of Prevnar™. ActHIB™ and Prevnar™ were administered intramuscularly in the right and left upper thighs, respectively.
The present invention relates to pharmaceutical compositions for preventing excitatory amino acids neurotoxicity comprising as active ingredient (3S,4S)-tetrahydrocannabinol (THC) type compounds of general formula (I), as hereunder defined.        The compositions of the present invention are particularly effective in alleviating and even preventing glutamate neurotoxicity due to acute to the central nervous system (CNS), such as injuries due to prolonged seizures, compromised or reduced blood supply, deprivation of glucose supply and mechanical trauma. The present compositions may also be effective in alleviating other damages to the CNS like poison-induced convulsions, considered to be associated with amino acids receptors other than that of glutamate, for example glycine.        The compositions of the present invention are also effective in the treatment of certain chronic degenerative diseases which are characterized by gradual selective neuronal loss. In this connection, the compositions of the present invention are contemplated as therapeutically effective in the treatment of the Alzheimer's disease.        The present compositions are of special value in grand mal seizures, global hypoxic ischemic insults, in hypoxia, alone or in combination with blood flow reduction (ischemia) as well as in cases of cardiac arrest and in cases of abrupt occlusion of cerebral arteries (stroke).      Some of the compounds according to formula (I), as will be hereinafter described in detail, are novel compounds and are claimed as such within the scope of the present application.      The active ingredient of the pharmaceutical compositions according to the present invention is a compound of the general formula;    having the (+)-(3S,4S) configuration, wherein A----B designates a 1(2) or a 6(1) double bond, R designates CH3 or CH2OH, R1 designates a hydrogen atom or a lower acyl group, and R2 designates (A) a straight-chained or branched C6-12alkyl radical; or (B) a group -O-R3, in which R3 is a straight-chained or branched C5-9alkyl radical or a straight-chained or branched alkyl radical substituted at the terminal carbon atom by a phenyl group.      Compounds of formula (I) in which R designates CH2OH and R1 designates a lower acyl group are novel compounds.
The invention provides a cimetidine composition for injection, and relates to the technical field of medicines and medicine manufacturing. Main medicines of the composition are cimetidine and melatonin. The melatonin comprises a quick release part and a slow release part contained in cyclodextrin. The cimetidine composition for injection provided by the invention has the functions of improving the treatment effect on upper gastrointestinal hemorrhage, shortening the course of treatment, further reducing the use level of cimetidine and lowering the side effect of cimetidine. Instability, fast distribution and elimination and the like of MT (Melatonin) caused by oral absorption are avoided, and the first pass effect of MT is reduced. Delivery design combining quick release and slow release meets the secretion characteristic of MT, solves the problem of short half life of MT and improves the bioavailability of the product.
Physical activity and sports can be considered important sources of motivation for people with visual impairments; however limited attention has been given to blind peoples' involvement in sports and to the intra-personal variables such as self-esteem and motivation that affect their sport participation. The purpose of the present study was a) to explore the relationship between self-esteem and intrinsic motivation in blind athletes, and b) to assess the levels of self-esteem and intrinsic motivation and identify differences in intrinsic motivation and self-esteem as a function of gender and sport type (individual-team sports). Participants were 78 (27 females) Greek blind athletes (30.29 ± 1.18 years of age) competing in team (N = 44) and individual (N = 34) sports. Participants completed the Intrinsic Motivation Inventory questionnaire (IMI) and Rosenberg Self-Esteem Scale (RSES) questionnaire. The findings revealed that high values on self-esteem could predict blind athletes' perceived competence (p = .001) and strengthen their intrinsic motivation while enabling them to regulate pressure and tension (p < .05). However, female athletes appeared to be more pressured than males (p < .05), and interestingly, team sport athletes scored higher in intrinsic motivation than individual sports athletes (p < .05). The findings provide useful insights regarding the role of self-esteem in blind athletes' motivational profiles and draw attention to the role of perceived competence in blind athletes' sporting experiences, emphasizing that team sport context may serve as a fertile ground for enhancing intrinsic motivation.